ClinicalTrials.gg
Active, not recruitingNCT03333187Updated Mar 30, 2025

Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability

A Phase 2 interventional study of Allogeneic stem cell transplantation and Ruxolitinib continuous therapy in Bone Marrow Fibrosis, sponsored by Universitätsklinikum Hamburg-Eppendorf. Active, not recruiting at 14 sites in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Universitätsklinikum Hamburg-Eppendorf · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Dec 2016, registered Jun 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
87
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies in Primary Myelofibrosis with a site in Germany — 15 open to participants now, 29 under way, 9 of them phase 3. Primary Myelofibrosis · Germany.

Enrollment
42nd of 70
87 · median 116
Started
2016
with 2 others
Phase 2
20 of 75
3 open now
Primary completion
2024-10
later than 4 of 28 live
Registered
35th of 75
by date

Among the 75 studies in Primary Myelofibrosis with a site in Germany, this one is the 42nd largest by enrollment of the 70 interventional ones that give a count, is one of 3 that started in 2016, is one of 20 in phase 2, reaches primary completion later than 4 of the 28 other live ones, and was the 35th registered.

Primary Myelofibrosis

626 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

15 of the 75 studies in Primary Myelofibrosis with a site in Germany are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Primary Myelofibrosis with a site in Germany, or all of them as a file.
02

Study summary

The present study will be a multicenter, prospective phase II-study comparing efficacy of allogeneic SCT for patients with myelofibrosis who have a suitable stem cell donor after a 3 months Ruxolitinib induction therapy with patients who lack a suitable stem cell donor and will continue to receive Ruxolitinib.

Read the detailed description

This study is a multicenter, prospective phase II-study compares efficacy of allogeneic SCT for patients with myelofibrosis who have a suitable stem cell donor after a 3 months Ruxolitinib induction therapy with patients who lack a suitable stem cell donor and will continue to receive Ruxolitinib.

In this study will further assess and compare the safety and efficacy of study treatments/ induction therapy in both study arms on spleen reduction, improvement of constitutional symptoms, QOL, toxicity, fibrosis regression, development of GvHD as well as chimerism, engraftment, relapse incidence, disease related mortality, outcome and overall survival.

03

Conditions studied

  • Bone Marrow Fibrosis

Keywords

  • Myelofibrosis, Myeloproliferative Disease
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Symptomatic primary myelofibrosis or myelofibrosis post polycythaemia vera or essential thrombocythemia stage intermediate 2- or high-risk according to IPSS or DIPSS [46] or intermediate 1-risk with high risk cytogenetics, other than normal karyotype, sole del 20q, del 13q, or sole+9, or transfusion-dependency
  2. Patients age: 18 - 70 years at time of inclusion (female and male)
  3. Patients understand and voluntarily sign an form
  4. count ≥ 50 x 109/L
  5. No prior Ruxolitinib treatment
  6. ≤ 2

Exclusion criteria

Exclusion Criteria:

  1. Severe renal, hepatic, pulmonary or cardiac disease, such as:

    • Total , or SGOT > 3 times upper the normal level
    • \< 30 %
    • \< 30 ml/min
    • DLCO \< 35 % and/or receiving supplementary continuous oxygen
  2. Positive serology for
  3. Pregnant or lactating women (positive serum pregnancy test)
  4. Age \< 18 and ≥ 71 years.
  5. Uncontrolled invasive fungal infection at time of screening (baseline)
  6. Serious psychiatric or psychological disorders
  7. Participation in another study with ongoing use of unlicensed product from 28 days before study enrollment
  8. Transformation to AML
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    Arm A

    Treatment with Allogeneic Stem cell Transplantation after 3 months of Ruxolitinib induction therapy

    Procedure: Allogeneic stem cell transplantation

  • Active comparator
    Arm B

    Treatment with Ruxolitinib continuous therapy

    Drug: Ruxolitinib continuous therapy

Interventions

06

What researchers measure

Primary outcomes

  1. Event free survival

    Compare to event free survival of patients at 3 years after allogeneic SCT and in Ruxolitinib continuous therapy in patients without a suitable donor

    Time frame: 3 years

Secondary outcomes

  1. Spleen reduction

    Ultrasound measurement Spleen size, reduction of Spleen size after 3 months Ruxolitinib induction therapy

    Time frame: 3 months

  2. Improvement of constitutional symptoms

    Improvement of constitutional symptoms (Loose of weight and night sweat) after 3 months Ruxolitinib induction therapy, questionnaire, medical history

    Time frame: 3 months

  3. Improvement of bone marrow fibrosis

    bone marrow histology, Improvement of bone marrow fibrosis after 3 months of Ruxolitinib induction therapy

    Time frame: 3 months

  4. Acute graft-versus-host disease

    Incidence of acute graft-versus-host disease on Day +100 after allogeneic SCT according to the Glucksberg scale revised by Przepiorka

    Time frame: Day +100 after allogeneic SCT

  5. Chronic graft-versus-host disease

    Incidence of chronic graft-versus-host disease according to the NIH consensus criteria of Filipovich et al. at 1, 2 and 3 years after allogeneic SCT

    Time frame: 1, 2 and 3 years after allogeneic SCT

  6. Toxicity of Ruxolitinib

    Toxicity of Ruxolitinib scored according to NCI CTCAE, Version 4.0

    Time frame: till 3 years

  7. Toxicity of conditioning therapy

    Toxicity of conditioning therapy scored according to NCI CTCAE, Version 4.0

    Time frame: till 3 years

  8. Relapse

    Cumulative incidence of relapse at 3 years after allogeneic SCT

    Time frame: 3 years

  9. Disease-related mortality

    Disease-related mortality at 3 years after allogeneic SCT and Ruxolitinib continuous therapies

    Time frame: 3 years

  10. Non-relapsed mortality

    Non-relapsed mortality at 1 and 3 years after allogeneic SCT and Ruxolitinib continuous therapy

    Time frame: 1 and 3 years

  11. Discontinuation rate

    Discontinuation rate at 3 years after Ruxolitinib continuous therapy (End of study)

    Time frame: 3 years

  12. Evaluation of Sorror Risk Score

    Evaluation of Sorror Risk Score on outcome after allogeneic SCT

    Time frame: at baseline

  13. Chimerism on relapse

    Chimerism Analyse, Impact of chimerism on relapse incidence after allogeneic SCT

    Time frame: 30d, 100d, 180 d, 1 year, 2 years and 3 years

  14. Bone marrow fibrosis regression

    bone marrow histology, Evaluation of bone marrow fibrosis regression after allogeneic SCT at 30d, 100d, 1 year, and 3 years

    Time frame: 30d, 100d, 1 year, and 3 years

  15. Bone marrow fibrosis regression

    bone marrow histology, Evaluation of bone marrow fibrosis regression after Ruxolitinib continuous therapy at 30d, 100d, 1 year and 3 years

    Time frame: 30d, 100d, 1 year and 3 years

  16. Evaluation of QOL (FACT-BMT)

    Questionnaire, Evaluation of QOL (FACT-BMT) before Ruxolitinib induction therapy (= baseline), at transplantation, and after transplantation at 6m, 1 year, 2 years and 3 years

    Time frame: baseline, at transplantation, +180d, +1 year, +2 years and +3 years

  17. Evaluation of QOL (MPN-SAF-TSS)

    Questionaire, Evaluation of QOL (MPN-SAF-TSS) before Ruxolitinib induction therapy (= baseline), at transplantation, and after transplantation at 6m, 1 year, 2 years and 3 years

    Time frame: baseline, at transplantation, +180d, +1 year, +2 years and +3 years

  18. Evaluation of QOL (FACT-BMT)

    Questionnaire, Evaluation of QOL (FACT-BMT) before Ruxolitinib induction therapy (= baseline), at confinement to Ruxolitinib continuous therapy and after confinement at 6 months, 1 year, 2 years and 3 years

    Time frame: baseline, confinement to Ruxolitinib continous therapy, +180d, +1 year, +2 years and +3 years

  19. Evaluation of QOL (MPN-SAF-TSS)

    Questionnaire, Evaluation of QOL (MPN-SAF-TSS) before Ruxolitinib induction therapy (= baseline), at confinement to Ruxolitinib continuous therapy and after confinement at 6 months, 1 year, 2 years and 3 years

    Time frame: baseline, confinement to Ruxolitinib continous therapy, +180d, +1 year, +2 years and +3 years

  20. Overall Survival

    Overall survival at 3 years after allogeneic SCT compared to Ruxolitinib continuous therapy in patients without a suit-able donor

    Time frame: 3 years

07

Study locations

14 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Oct 2024, 93 months.

Of 68 non-industry phase 2 interventional studies under Primary Myelofibrosis, half reached primary completion within 83 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 119. This study's 93 months is above that.

Counting every sponsor, half of 98 studies reached it within 66 months; a quarter within 32 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2017
First posted
Nov 6, 2017
StartActual
Dec 21, 2016
Primary completionActual
Oct 7, 2024
CompletionEst.
Oct 7, 2025
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03333187
Collaborators
Novartis, Clinical Trial Center North (CTC North GmbH & Co. KG)
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Dec 21, 2016
Primary completion
Oct 7, 2024
Completion
Oct 7, 2025 (estimated)
Last update
Mar 30, 2025

Study contacts

Nicolaus Kröger, Prof. Dr.
principal investigator · Universitätsklinikum Hamburg-Eppendorf

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion